211 related articles for article (PubMed ID: 36232292)
21. Adenosine Kinase Inhibition Augments Conducted Vasodilation and Prevents Left Ventricle Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.
Davila A; Tian Y; Czikora I; Li J; Su H; Huo Y; Patel V; Robinson V; Kapuku G; Weintraub N; Bagi Z
Circ Heart Fail; 2019 Aug; 12(8):e005762. PubMed ID: 31525084
[TBL] [Abstract][Full Text] [Related]
22. Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.
Bayes-Genis A; Iborra-Egea O; Spitaleri G; Domingo M; Revuelta-López E; Codina P; Cediel G; Santiago-Vacas E; Cserkóová A; Pascual-Figal D; Núñez J; Lupón J
Sci Rep; 2021 Jun; 11(1):12025. PubMed ID: 34103605
[TBL] [Abstract][Full Text] [Related]
23. Effects of Triiodothyronine Treatment in an Animal Model of Heart Failure with Preserved Ejection Fraction.
Neves JS; Leite AR; Conceição G; Gonçalves A; Borges-Canha M; Vale C; Von-Hafe M; Martins D; Miranda-Silva D; Leite S; Rocha-Oliveira E; Sousa-Mendes C; Chaves J; Lourenço IM; Grijota-Martínez C; Bárez-López S; Miranda IM; Almeida-Coelho J; Vasques-Nóvoa F; Carvalho D; Lourenço A; Falcão-Pires I; Leite-Moreira A
Thyroid; 2023 Aug; 33(8):983-996. PubMed ID: 37140469
[No Abstract] [Full Text] [Related]
24. A directed network analysis of the cardiome identifies molecular pathways contributing to the development of HFpEF.
Summer G; Kuhn AR; Munts C; Miranda-Silva D; Leite-Moreira AF; Lourenço AP; Heymans S; Falcão-Pires I; van Bilsen M
J Mol Cell Cardiol; 2020 Jul; 144():66-75. PubMed ID: 32422321
[TBL] [Abstract][Full Text] [Related]
25. Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction.
Saw EL; Werner LD; Zamani P; Chirinos JA; Valero-Muñoz M; Sam F
Front Cardiovasc Med; 2022; 9():1016452. PubMed ID: 36531739
[TBL] [Abstract][Full Text] [Related]
26. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin.
Aimo A; Senni M; Barison A; Panichella G; Passino C; Bayes-Genis A; Emdin M
Heart Fail Rev; 2023 Jan; 28(1):179-191. PubMed ID: 35488030
[TBL] [Abstract][Full Text] [Related]
27. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle.
Bowen TS; Rolim NP; Fischer T; Baekkerud FH; Medeiros A; Werner S; Brønstad E; Rognmo O; Mangner N; Linke A; Schuler G; Silva GJ; Wisløff U; Adams V;
Eur J Heart Fail; 2015 Mar; 17(3):263-72. PubMed ID: 25655080
[TBL] [Abstract][Full Text] [Related]
28. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
[TBL] [Abstract][Full Text] [Related]
29. Skeletal muscle alterations in HFrEF vs. HFpEF.
Adams V; Linke A; Winzer E
Curr Heart Fail Rep; 2017 Dec; 14(6):489-497. PubMed ID: 28940089
[TBL] [Abstract][Full Text] [Related]
30. Acetylation and phosphorylation changes to cardiac proteins in experimental HFpEF due to metabolic risk reveal targets for treatment.
Koser F; Hobbach AJ; Abdellatif M; Herbst V; Türk C; Reinecke H; Krüger M; Sedej S; Linke WA
Life Sci; 2022 Nov; 309():120998. PubMed ID: 36179815
[TBL] [Abstract][Full Text] [Related]
31. Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by Circulating Cytokines?
Seiler M; Bowen TS; Rolim N; Dieterlen MT; Werner S; Hoshi T; Fischer T; Mangner N; Linke A; Schuler G; Halle M; Wisloff U; Adams V
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27609832
[TBL] [Abstract][Full Text] [Related]
32. Disturbed cardiac mitochondrial and cytosolic calcium handling in a metabolic risk-related rat model of heart failure with preserved ejection fraction.
Miranda-Silva D; Wüst RCI; Conceição G; Gonçalves-Rodrigues P; Gonçalves N; Gonçalves A; Kuster DWD; Leite-Moreira AF; van der Velden J; de Sousa Beleza JM; Magalhães J; Stienen GJM; Falcão-Pires I
Acta Physiol (Oxf); 2020 Mar; 228(3):e13378. PubMed ID: 31520455
[TBL] [Abstract][Full Text] [Related]
33. Renal injury in relation to obesity and the additive effect of hypertension in female and male obese and lean ZSF1 rats.
Nguyen ITN; Cramer MJ; Joles JA; Verhaar MC
Am J Physiol Renal Physiol; 2023 Jul; 325(1):F73-F86. PubMed ID: 37227224
[TBL] [Abstract][Full Text] [Related]
34. Histological and haemodynamic characterization of right ventricle in sedentary and trained rats with heart failure with preserved ejection fraction.
Oliveira MI; Leite S; Barros A; Lourenço AP; Mendes C; Schmidt C; Santos M; Leite-Moreira A; Moreira-Gonçalves D
Exp Physiol; 2021 Dec; 106(12):2457-2471. PubMed ID: 34676608
[TBL] [Abstract][Full Text] [Related]
35. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.
Hamdani N; Franssen C; Lourenço A; Falcão-Pires I; Fontoura D; Leite S; Plettig L; López B; Ottenheijm CA; Becher PM; González A; Tschöpe C; Díez J; Linke WA; Leite-Moreira AF; Paulus WJ
Circ Heart Fail; 2013 Nov; 6(6):1239-49. PubMed ID: 24014826
[TBL] [Abstract][Full Text] [Related]
36. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
[TBL] [Abstract][Full Text] [Related]
37. Both male and female obese ZSF1 rats develop cardiac dysfunction in obesity-induced heart failure with preserved ejection fraction.
Nguyen ITN; Brandt MM; van de Wouw J; van Drie RWA; Wesseling M; Cramer MJ; de Jager SCA; Merkus D; Duncker DJ; Cheng C; Joles JA; Verhaar MC
PLoS One; 2020; 15(5):e0232399. PubMed ID: 32374790
[TBL] [Abstract][Full Text] [Related]
38. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
[TBL] [Abstract][Full Text] [Related]
39. Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction.
Leite S; Moreira-Costa L; Cerqueira R; Sousa-Mendes C; Angélico-Gonçalves A; Fontoura D; Vasques-Nóvoa F; Leite-Moreira AF; Lourenço AP
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):690-701. PubMed ID: 34328815
[TBL] [Abstract][Full Text] [Related]
40. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
